Valuation: THERACLION N

Market Cap 47.15M 54.95M 44.24M 40.42M 76.24M 5.24B 76.51M 524M 203M 2.65B 206M 202M 8.75B P/E 2024
-2.66x
P/E 2025 -6.33x
Enterprise Value 55.01M 64.1M 51.6M 47.15M 88.94M 6.12B 89.25M 611M 237M 3.09B 241M 235M 10.21B EV / Sales 2024
22.5x
EV / Sales 2025 55.4x
Free-Float
39.01%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer - 2023-05-23
Director of Finance/CFO - -
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member - 2021-06-21
Director/Board Member - 2022-01-27
Director/Board Member - 2023-06-28
Change 5-day change 1-year change 3-year change Capi.($)
+0.89%+7.58%+29.13%+17.01% 232B
-0.28%+7.91%+3.67%-15.72% 152B
-0.38%-5.31%-20.92%+24.49% 131B
-3.39%-4.56%-54.17%-5.10% 72.26B
-1.11%-0.51%-17.42%-13.58% 51.57B
-0.10%-0.22%+12.27%+19.18% 52.38B
+0.20%+4.47%+30.16%+29.58% 43.71B
-0.07%+3.22%+38.54%+51.51% 40.72B
-0.07%+19.41%+125.61%+42.23% 33.97B
Average +0.19%+3.90%+16.32%+16.62% 90.01B
Weighted average by Cap. +0.37%+3.71%+9.33%+11.78%

Financials

2024 2025
Net sales 830K 968K 779K 712K 1.34M 92.33M 1.35M 9.22M 3.58M 46.61M 3.63M 3.55M 154M 652K 760K 612K 559K 1.05M 72.51M 1.06M 7.24M 2.81M 36.6M 2.85M 2.79M 121M
Net income -5.76M -6.71M -5.4M -4.93M -9.31M -640M -9.34M -63.92M -24.8M -323M -25.19M -24.64M -1.07B -5.69M -6.63M -5.34M -4.88M -9.2M -633M -9.23M -63.17M -24.51M -319M -24.89M -24.35M -1.06B
Net Debt 3.41M 3.97M 3.2M 2.92M 5.51M 379M 5.53M 37.87M 14.69M 191M 14.92M 14.6M 633M 7.85M 9.15M 7.37M 6.73M 12.7M 873M 12.74M 87.18M 33.82M 441M 34.35M 33.6M 1.46B
Logo THERACLION N
Theraclion specializes in developping, manufacturing and marketing echotherapy equipment associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules.Net sales break down by activity as follows: - sale of consumables (52.8%); - sale of equipment (28.8%); - provision of after-sales services (18.4%). The vast majority of net sales are earned abroad.
Employees
-